Frontlight ResearchEarly access
Follicular lymphoma trials in Italy
22 of 26 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Where
- Brescia, Meldola, Milan, Naples, Rozzano
- Age
- 18 years and over
- People
- 130 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00 - Phase 1/2Taking peopleA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Where
- Candiolo, Milan, Naples, Reggio Emilia, Rome, Rozzano
- Age
- 18 years and over
- People
- 280 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07519772 · EU 2025-523005-15-00 - Phase 2/3Taking peopleA Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Where
- Candiolo, Rome
- Age
- 18 years and over
- People
- 960 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07634471 · EU 2025-522777-10-00 - Phase 3Taking peopleA Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- Where
- Ascoli Piceno, Bologna, Brescia, Candiolo, Genoa, Meldola, Milan, Naples, Novara, Ravenna, Tricase, Udine, Varese
- Age
- 18 years and over
- People
- 822 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06091254 · EU 2022-502660-20-00 - Phase 3Active, not recruitingA Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- Where
- Aviano, Bologna, Brescia, Candiolo, Genoa, Meldola, Milan, Modena, Monza, Naples, Novara, Pavia, Perugia, Ravenna, Reggio Emilia, Rome, Turin, Udine
- Age
- 18 years and over
- People
- 580 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT06149286 · EU 2022-503092-28-00 - Phase 1/2Active, not recruitingAn early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- Where
- Bergamo, Bologna, Naples
- Age
- 18 years and over
- People
- 204 worldwide
- Run by
- Celgene Corp.
See details and how to joinNCT03930953 · EU 2024-515690-10-00 - Phase 1Not yet taking people in ItalyA Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Where
- Bologna, Naples, Rozzano
- Age
- 18 years and over
- People
- 215 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07101328 · EU 2025-524180-20-00 - Phase 1Not yet taking people in ItalyA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
- Where
- Bologna, Milan
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00 - Phase 1Taking peopleIKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
- Where
- Candiolo, Milan
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659 - Phase 1Not yet taking people in ItalyA Study of ARC-02 in B-cell NHL
- Where
- Aviano, Bergamo, Bologna, Rozzano
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00 - Phase 3Taking peopleA Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- Where
- Bologna, Guastalla, Milan, Rozzano, Trieste
- Age
- 18 years to 130 years
- People
- 1,018 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06549595 · EU 2023-510098-33-01 - Phase 2Taking peopleSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
- Where
- Alexandria, Bologna, Busto Arsizio, Milan
- Age
- 18 years and over
- People
- 270 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06526793 · EU 2023-505789-27-00 - Phase 1/2Taking peopleA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Where
- Bologna, Milan, Roma, Verona
- Age
- 18 years and over
- People
- 689 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00 - Phase 1/2Taking peopleA Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Where
- Bologna, Milan
- Age
- 18 years and over
- People
- 174 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06542250 - Phase 3Taking peopleComparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
- Where
- Alessandria, Avellino, Aviano, Bari, Biella, Brescia, Cagliari, Candiolo, Castelfranco Veneto, Catania, Cuneo, Florence, Ivrea, Latina, Meldola, Messina, Milan, Modena, Monza, Naples, Novara, Padova, Palermo, Pavia, Perugia, Piacenza, Pisa, Ravenna, Reggio Emilia, Rimini, Roma, Sassuolo, Siena, Sondrio, Terni, Treviso, Udine, Varese, Verona
- Age
- 18 years and over
- People
- 190
- Run by
- Fondazione Italiana Linfomi - ETS
See details and how to joinNCT05929222 - Phase 2Not yet taking people in ItalyCombining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Where
- Bologna, Milan, Naples
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Universität Münster
See details and how to joinNCT07197307 · EU 2023-509861-19-01 - Phase 1Taking peopleA Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Where
- Bologna, Brescia, Milan, Rome
- Age
- 18 years and over
- People
- 572 worldwide
- Run by
- Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00 - Phase 3Taking peoplePhase III trial comparing local radiotherapy alone or with Obinutuzumab in early stage Follicular Lymphoma: the GAZEBO Trial.
- Where
- Alexandria, Avellino, Aviano, Bari, Brescia, Cagliari, Candiolo, Castelfranco Veneto, Catania, Chivasso, Cuneo, Florence, Latina, Meldola, Messina, Milan, Modena, Monza, Naples, Novara, Padova, Palermo, Pavia, Perugia, Piacenza, Pisa, Ponderano, Ravenna, Reggio Emilia, Rimini, Roma, Rome, Sassuolo, Siena, Sondrio, Terni, Treviso, Udine, Varese, Verona
- Age
- 18 years and over
- People
- 190
- Run by
- Fondazione Italiana Linfomi Onlus
See details and how to join2022-502775-29-01 - Phase 2Taking peopleEfficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
- Where
- Turin
- Age
- 18 years to 70 years
- People
- 213 worldwide
- Run by
- Miltenyi Biomedicine GmbH
See details and how to joinNCT04844866 · EU 2023-506270-13-00 - Phase 3Taking peopleA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
- Where
- Alexandria, Bologna, Meldola, Naples, Pisa, Rozzano, Turin
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Celgene
See details and how to joinNCT06911502 · EU 2024-519152-82-00 - No phaseNot yet taking people in ItalyGeriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment
- Where
- Ancona, Avellino, Aviano, Bari, Brescia, Cagliari, Florence, Milan, Monza, Padova, Palermo, Parma, Piacenza, Prato, Ravenna, Reggio Emilia, Roma, Siena, Teramo, Torino, Udine, Verona
- Age
- 70 years and over
- People
- 170
- Run by
- Fondazione Italiana Linfomi - ETS
See details and how to joinNCT07476105 - Phase 1Taking peopleStudy of SGR-1505 in Mature B-Cell Neoplasms
- Where
- Alexandria, Milan, Turin, Verona
- Age
- 18 years and over
- People
- 98 worldwide
- Run by
- Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00